Education
About Us
Working with TipRanks
Follow Us
Eagle Pharmaceuticals Inc (EGRX)
OTHER OTC:EGRX
Total Valuation
Eagle Pharmaceuticals has a market cap or net worth of $29.87M. The enterprise value is ―.
Market Cap$29.87M
Enterprise Value―
Share Statistics
Eagle Pharmaceuticals has 12,986,971 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,986,971
Owned by Insiders17.60%
Owned by Institutions0.10%
Financial Efficiency
Eagle Pharmaceuticals’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 15.51%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)15.51%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee2.36M
Profits Per Employee265.99K
Employee Count134
Asset Turnover0.78
Inventory Turnover1.99
Valuation Ratios
The current PE Ratio of Eagle Pharmaceuticals is 10.61. Eagle Pharmaceuticals’s PEG ratio is 0.00.
PE Ratio10.61
PS Ratio0.00
PB Ratio0.00
Price to Fair Value1.62
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.00
Income Statement
In the last 12 months, Eagle Pharmaceuticals had revenue of 316.61M and earned 35.64M in profits. Earnings per share was 2.76.
Revenue316.61M
Gross Profit221.67M
Operating Income80.96M
Pretax Income61.43M
Net Income35.64M
EBITDA106.83M
Earnings Per Share (EPS)2.76
Cash Flow
In the last 12 months, operating cash flow was -9.32M and capital expenditures -74.00K, giving a free cash flow of -9.39M billion.
Operating Cash Flow-9.32M
Free Cash Flow-9.39M
Free Cash Flow per Share-0.72
Dividends & Yields
Eagle Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.57
52-Week Price Change-40.89%
50-Day Moving Average1.81
200-Day Moving Average1.61
Relative Strength Index (RSI)66.31
Average Volume (3m)3.58K
Important Dates
Eagle Pharmaceuticals upcoming earnings date is Nov 4, 2024, TBA Not Confirmed.
Last Earnings DateAug 6, 2024
Next Earnings DateNov 4, 2024
Ex-Dividend Date―
Financial Position
Eagle Pharmaceuticals as a current ratio of 1.70, with Debt / Equity ratio of 0.00%
Current Ratio1.70
Quick Ratio1.27
Debt to Market Cap0.17
Net Debt to EBITDA0.16
Interest Coverage Ratio20.01
Taxes
In the past 12 months, Eagle Pharmaceuticals has paid 25.79M in taxes.
Income Tax25.79M
Effective Tax Rate0.42
Enterprise Valuation
Eagle Pharmaceuticals EV to EBITDA ratio is 5.04, with an EV/FCF ratio of 7.73.
EV to Sales1.23
EV to EBITDA5.04
EV to Free Cash Flow7.73
EV to Operating Cash Flow7.70
Balance Sheet
Eagle Pharmaceuticals has $15.35M in cash and marketable securities with $71.61M in debt, giving a net cash position of $56.26M billion.
Cash & Marketable Securities$15.35M
Total Debt$71.61M
Net Cash$56.26M
Net Cash Per Share$4.33
Tangible Book Value Per Share$5.43
Margins
Gross margin is 0.00%, with operating margin of 25.57%, and net profit margin of 11.26%.
Gross Margin0.00%
Operating Margin25.57%
Pretax Margin19.40%
Net Profit Margin11.26%
EBITDA Margin24.48%
EBIT Margin20.68%
Analyst Forecast
The average price target for Eagle Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―